Addus HomeCare Corp (ADUS) · Nov 3, 2026 · Earnings
Beat — Adjusted EPS $1.83 vs ~$1.79 consensus
Addus HomeCare earnings show an adjusted EPS beat, but revenue narrowly missed consensus amid slower hospice growth and a pending acquisition.
Addus HomeCare is scaling a multi-state home-care platform, led by personal care and supported by hospice and home health, while preparing to integrate the pending AccentCare personal-care acquisition. The third quarter mostly supports that strategy, but the headline result is mixed against expectations.
The earnings beat came from profit conversion, not revenue acceleration. Adjusted diluted EPS was $1.83 versus published consensus of about $1.79, while revenue was $387.7 million versus consensus of about $388.7 million. That is a narrow profit beat alongside a small top-line miss, so this is better read as healthy execution than a broad upside surprise. The company said, “Adjusted net income per diluted share was $1.83 compared with $1.56 for the prior-year period.”
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net service revenue (Income Statement Information) | $387.7M | $362.3M | ~$388.7M |
| Adjusted diluted EPS (Reconciliation of Net Income per Diluted Share) | $1.83 | $1.56 | ~$1.79 |
| Adjusted EBITDA (Reconciliation of Adjusted EBITDA) | $51.2M | $45.1M | |
| Personal care organic revenue (Personal Care operating data) | 6.9% | 6.6% | |
| Hospice organic revenue (Reconciliation of Adjusted Hospice Organic Revenue Growth) | 8.8% |
Personal care remains the engine, while hospice is less clean than the headline suggests. Personal-care revenue grew to $301.0 million and organic revenue growth improved to 6.9%, helped by higher billable hours and rates. Hospice average daily census increased 4.3%, but reported hospice revenue growth was only 4.1%; the stronger 8.8% adjusted figure excludes the comparison-period benefit from implicit price concessions. The company said, “Personal care services continued to drive our growth, accounting for 77.6% of our third quarter revenues.” 〔0〕
The AccentCare deal is strategically important but not new information in this filing. Addus had already announced the approximately $275 million cash acquisition on September 14, 2026; this release mainly confirms the transaction remains pending and frames it as a roughly $280 million annualized-revenue expansion. The balance sheet can support the deal: the company reported $98.5 million of cash, $24.3 million of bank debt, and $617.8 million of revolver availability. The company said, “This transaction will add roughly $280 million in annualized revenue, a nearly 19% expansion of our total revenue base.”
Bottom line: Addus delivered a modest adjusted-EPS beat, but the slight revenue miss keeps this from being a clean upside quarter. The operating story remains intact—personal care growth, improving home health trends, and ample financing capacity for AccentCare—but the filing advances that story only modestly versus what was already expected.
Earnings call, November 4, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!